Viral hepatitis: Global goals for vaccination

Journal of Clinical Virology

Volumn 55, Issue 4, 2012, Pages 296-302

  Lavanchy, Daniel ^a  

^a NONE   (Switzerland)

Author keywords

Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis E; Immunization; Prevention; Vaccines

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HEPATITIS E VACCINE; HEPATITIS VACCINE;

CANCER PREVENTION; DELTA AGENT HEPATITIS; ENDEMIC DISEASE; EPIDEMIOLOGICAL DATA; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HEALTH PROMOTION; HEPATITIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HIGH RISK POPULATION; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS HEPATITIS;

EID: 84867873277     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.08.022     Document Type: Review

References (120)

1. Hepatitis A vaccines. WHO position paper. Wkly Epidemiol Rec 2000, 75:38-43.
2. Shouval D. Hepatitis A. The immunological basis for immunization series. Module 18 2011, WHO, Geneva, p. 1-50.
3. Mead P.S., Slutsker L., Dietz V., McCaig L.F., Bresee J.S., Shapiro C., et al. Food-related illness and death in the United States. Emerg Infect Dis 1999, 5:607-625.
4. Cheinquer H., Targa Ferreira C.H., Cheinquer N. HAV epidemiology in the southern hemisphere. Hot Top Viral Hepat 2007, 7:21-25.
5. Frosner G.G., Papaevangelou G., Bütler R., Iwarson S., Lindholm A., Couroucé-Pauty A., et al. Antibodies against hepatitis A in different European countries. I. Comparison of prevalence data in different age groups. Am J Epidemiol 1979, 110:63-69.
6. Papaevangelou G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine 1992, 10(Suppl. 1):S63-S66.
7. Steffen R., Kane M.A., Shapiro C.N., Billo N., Schoellhorn K.J., van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994, 272:885-889.
8. Hendrickx G., Van Herck K., Vorsters A., Wiersma S., Shapiro C., Andrus J.K., et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepat 2008, 15(Suppl. 2):1-15.
9. World Health Organization Foodborne disease outbreaks: guidelines for investigation and control 2008, WHO Press, Geneva.
10. Fiore A.E., Wasley A., Bell B.P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006, 55:1-23.
11. Bovier P.A., Bock J., Ebengo T.F., Frosner G., Glaus J., Herzog C., et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 2010, 82:1629-1634.
12. Werzberger A., Mensch B., Nalin D.R., Kuter B.J. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine 2002, 20:1699-1701.
13. Werzberger A., Kuter B., Shouval D., Mensch B., Brown L., Wiens B., et al. Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial. J Hepatol 1993, 18(Suppl. 2):S46-S50.
14. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C.A., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994, 271:1328-1334.
15. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362:1065-1071.
16. Ott J.J., Irving G., Wiersma S.T. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine 2012, in press. 10.1016/j.vaccine.2012.04.104.
17. Van Damme P.A., Van Herck K., Banatvala J.E. Do we need hepatitis A booster vaccinations?. J Travel Med 2004, 11:179-180.
18. Van Damme P., Van Herck K. Effect of hepatitis A vaccination programs. JAMA 2005, 294:246-248.
19. Bonanni P., Boccalini S., Bechini A. Vaccination against hepatitis A: a review of the evidence. Hot Top Viral Hepat 2007, 7:33-37.
20. International travel and health 2008 2008, World Health Organization.
21. Nothdurft H.D., Zuckerman J., Stoffel M., Dieussaert I., Van Damme P. Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travelers. J Travel Med 2004, 11:260-261.
22. CDC Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006, 55:1-23.
23. Victor J.C., Monto A.S., Surdina T.Y., Suleimenova S.Z., Vaughan G., Nainan O.V., et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007, 357:1685-1694.
24. Bonanni P., Colombai R., Franchi G., Lo Nostro A., Comodo N., Tiscione E. Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. Epidemiol Infect 1998, 121:377-380.
25. Bonanni P., Franzin A., Staderini C., Pitta M., Garofalo G., Cecconi R., et al. Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy?. Vaccine 2005, 23:2176-2180.
26. CDC Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999, 48:1-38.
27. McMahon B.J., Beller M., Williams J., Schloss M., Tanttila H., Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996, 150:733-739.
28. Prikazsky V., Olear V., Cernoch A., Safary A., Andre F.E. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 1994, 44:457-459.
29. Selnikova O., Moisseeva A., Zadorozhnaja V., Dokachenko A., Kachur N., Gavrik S. Hepatitis A vaccination effectiveness during an outbreak in the Ukraine. Vaccine 2008, 26:3135-3137.
30. Zamir C., Rishpon S., Zamir D., Leventhal A., Rimon N., Ben-Porath E. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur J Clin Microbiol Infect Dis 2001, 20:185-187.
31. Samandari T., Bell B.P., Armstrong G.L. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004, 22:4342-4350.
32. Hollinger F.B., Bell B., Levy-Bruhl D., Shouval D., Wiersma S., Van Damme P. Hepatitis A and B vaccination and public health. J Viral Hepat 2007, 14(Suppl. 1):1-5.
33. Koff R.S. Hepatitis A. Lancet 1998, 351:1643-1649.
34. Lemon S.M. Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clin Chem 1997, 43:1494-1499.
35. Dagan R., Leventhal A., Anis E., Slater P., Ashur Y., Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005, 294:202-210.
36. Temte J.L. Should all children be immunised against hepatitis A?. BMJ 2006, 332:715-718.
37. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005, 34:S1-S3.
38. Gay N., Edmunds W., Bah E., Nelson C. Estimating the global burden of hepatitis B 2001, World Health Organization, Department of Vaccines and Biologicals, Geneva.
39. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
40. Kane A., Lloyd J., Zaffran M., Simonsen L., Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Org 1999, 77:801-807.
41. WHO Global status of immunization safety: report based on the WHO/UNICEF joint reporting. Wkly Epidemiol Rec 2005, 80:361-368.
42. VHPB (Viral Hepatitis Prevention Board) Hepatitis B vaccination: safety issues. Viral Hepat 2003, 12:1-14.
43. Prüss-Ustün A., Rapiti E., Hutin Y. Sharps injuries: global burden of disease from sharps injuries to health-care workers. WHO Environmental Burden of Disease Series 2003, World Health Organization, Geneva.
44. Hutin Y.J., Chen R.T. Injection safety: a global challenge. Bull World Health Org 1999, 77:787-788.
45. Hutin Y.J., Duclos P., Hogerzeil H., Ball A., Carr R. Unsterile injections and emergence of human pathogens. Lancet 2002, 359:2280.
46. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142:333-341.
47. Wait S., Chen D.S. Towards the eradication of hepatitis B in Taiwan. Kaohsiung J Med Sci 2012, 28:1-9.
48. Tajiri H., Tanaka H., Brooks S., Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control 2011, 22:523-527.
49. Viviani S., Carrieri P., Bah E., Hall A.J., Kirk G.D., Mendy M., et al. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:3216-3223.
50. Lee C.L., Ko Y.C. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997, 99:351-353.
51. Bonanni P., Pesavento G., Bechini A., Tiscione E., Mannelli F., Benucci C., et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003, 21:685-691.
52. Namgyal P. Impact of hepatitis B immunization, Europe and worldwide. J Hepatol 2003, 39(Suppl. 1):S77-S82.
53. Tsebe K.V., Burnett R.J., Hlungwani N.P., Sibara M.M., Venter P.A., Mphahlele M.J. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001, 19:3919-3926.
54. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
55. Chien Y.C., Jan C.F., Kuo H.S., Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006, 28:126-135.
56. Chang M.H. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 2003, 23:309-314.
57. Francois G., Duclos P., Margolis H., Lavanchy D., Siegrist C.A., Meheus A., et al. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J 2005, 24:953-961.
58. Lavanchy D. Hepatitis B vaccines and immunization. Textbook in hepatology 2007, vol. 1:907-916. Blackwell.
59. European Consensus Group on Hepatitis B Immunity Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565.
60. FitzSimons D., Francois G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23:4158-4166.
61. Zanetti A.R., Mariano A., Romano L., d'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366:1379-1384.
62. John T.J., Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations?. J Gastroenterol Hepatol 2005, 20:5-10.
63. Shouval D. Hepatitis B vaccines. J Hepatol 2003, 39(Suppl. 1):S70-S76.
64. Kidney Disease Improving Global Outcomes KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008, 73:S1-S99.
65. VHPB (Viral Hepatitis Prevention Board) Combined hepatitis B vaccines. Viral Hepatitis 2002, 10:1-20.
66. Chunsuttiwat S., Biggs B.A., Maynard J.E., Thammapormpilas P., O-Prasertsawat M. Comparative evaluation of a combined DTP-HB vaccine in the EPI in Chiangrai Province, Thailand. Vaccine 2002, 21:188-193.
67. Ramkissoon A., Coovadia H.M., Jugnundan P., Willems P., Clemens B.R. A new combined DTP-HBV-Hib vaccine-strategy for incorporation of Hib vaccination into childhood immunisation programmes. S Afr Med J 2001, 91:864-869.
68. Nolan T., Hogg G., Darcy M.A., Skeljo M., Carlin J., Boslego J. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity. Vaccine 2001, 19:2127-2137.
69. Papaevangelou G. Current combined vaccines with hepatitis B. Vaccine 1998, 16(Suppl.):69-72.
70. Mele A., Tancredi F., Romano L., Giuseppone A., Colucci M., Sangiuolo A., et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 2001, 184:905-908.
71. Zanetti A.R., Dentico P., Del Vecchio Blanco C., Sagnelli E., Villa E., Ferroni P., et al. Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. Final report. J Med Virol 1986, 18:327-334.
72. Hill J.B., Sheffield J.S., Kim M.J., Alexander J.M., Sercely B., Wendel G.D. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002, 99:1049-1052.
73. Lolekha S., Warachit B., Hirunyachote A., Bowonkiratikachorn P., West D.J., Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002, 20:3739-3743.
74. Harpaz R., McMahon B.J., Margolis H.S., Shapiro C.N., Havron D., Carpenter G., et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000, 181:413-418.
75. Hsu H.M., Chen D.S., Chuang C.H., Lu J.C., Jwo D.M., Lee C.C., et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988, 260:2231-2235.
76. Mahoney F.J., Kane M. Hepatitis B vaccine. Vaccines 1999, 158-182. WB Saunders Company, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
77. Hollinger F.B., Liang T.J. Hepatitis B virus. Fields virology 2001, vol. 4:2971-3036. Lippincott Williams & Wilkins, Philadelphia.
78. Global Advisory Committee on Vaccine Safety Wkly Epidemiol Rec 2002, 77:389-404.
79. Marwick C., Mitka M. Debate revived on hepatitis B vaccine value. JAMA 1999, 282:15-17.
80. WHO Expanded Programme on Immunization (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec 1997, 72:149-152.
81. Ascherio A., Zhang S.M., Hernan M.A., Olek M.J., Coplan P.M., Brodovicz K., et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001, 344:327-332.
82. Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol 2003, 39(Suppl.1):S83-S88.
83. WHO, UNICEF, World Bank State of the world's vaccines and immunization 2009, World Health Organization, Geneva. 3rd ed.
84. Piorkowsky N.Y. Europe's hepatitis challenge: defusing the " viral time bomb" J Hepatol 2009, 51:1068-1073.
85. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995, 13:S47-S49.
86. Grosheide P., van Damme P. Prevention and control of hepatitis B in the community. Commun Dis Ser 1996, 1:1-60.
87. Scientific Advisory Group of Experts (SAGE) Hepatitis B control through immunization 1996, WHO Global Programme for Vaccines and Immunization, Geneva, (GPV/SAGE.96/WP.02).
88. Prince A.M. Control of hepatitis B virus infection in Third-World countries. Transfus Med Rev 1990, 4:187-190.
89. Mahoney F.J. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999, 12:351-366.
90. van Steenbergen J.E. Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners. J Hepatol 2002, 37:507-513.
91. Zanetti A.R., Tanzi E., Romano L., Grappasonni I. Vaccination against hepatitis B: the Italian strategy. Vaccine 1993, 11:521-524.
92. Zuckerman A.J. Hepatitis viruses. Medical microbiology 1996, 849-863. The University of Texas Medical Branch at Galveston, Galveston. 4rd ed. S. Baron (Ed.).
93. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855-1859.
94. Stroffolini T., Mele A., Tosti M.E., Gallo G., Balocchini E., Ragni P., et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000, 33:980-985.
95. Gatcheva N., Vladimirova N., Kourtchatova A. Implementing universal vaccination programmes: Bulgaria. Vaccine 1995, 13(Suppl. 1):S82-S83.
96. UNICEF & WHO Immunization summary. A statistical reference containing data through 2010 2012, UNICEF, Geneva, New York.
97. UNICEF & WHO Global Immunization Vision and Strategy 2006-2015 2005, World Health Organization, Geneva.
98. Kammerlander R., Vaudaux B., Bourquin C., Zimmermann H.P., Raeber P.A. Vaccination contre l'hépatite B en Suisse: vers une stratégie globale. Rev Med Suisse Romande 1998, 118:335-339.
99. Alter M.J. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003, 23:39-46.
100. Bonanni P. Universal hepatitis B immunization: infant, and infant plus adolescent immunization. Vaccine 1998, 16:S17-S22.
101. Tepper M.L. Universal hepatitis B immunization: young adolescent immunization. Vaccine 1998, 16:S23-S26.
102. WHO Hepatitis B immunization. Introducing hepatitis B into national immunization services. Fact sheet WHO/V&B/01 2001.
103. Hipgrave D.B., Maynard J.E., Biggs B.A. Improving birth dose coverage of hepatitis B vaccine. Bull World Health Org 2006, 84:65-71.
104. Getting started with vaccine vial monitors 2002, World Health Organization. Vaccines and Biologicals, Geneva, p. 1-29.
105. Henderson D.A. Lessons from the eradication campaigns. Vaccine 1999, 17(Suppl. 3):53-55.
106. Bonanni P., Colombai R., Gasparini R., Lo Nostro A., Tiscione E., Tomei A., et al. Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatr Infect Dis J 1999, 18:677-682.
107. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(Suppl. 1):74-81.
108. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011, 239:99-108.
109. Houghton M. Chimp virus makes a savvy vaccine vector. Sci Transl Med 2012, 4:115fs1.
110. Feinstone S.M., Hu D.J., Major M.E. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis 2012, 55(Suppl. 1):S25-S32.
111. Rizzetto M., Smedile A. Hepatitis D. Diseases of the liver 2002, 863-875. Lippincott Williams and Wilkins, Philadelphia. E. Schiff, M. Sorrell, W. Maddrey (Eds.).
112. Aggarwal R. The global prevalence of hepatitis E virus infection and susceptibility: a systematic review 2010, World Health Organization, Geneva.
113. Purcell R.H., Emerson S.U. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008, 48:494-503.
114. Rein D.B., Stevens G.A., Theaker J., Wittenborn J.S., Wiersma S.T. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012, 55:988-997.
115. Shrestha M.P., Scott R.M., Joshi D.M., Mammen M.P., Thapa G.B., Thapa N., et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007, 356:895-903.
116. Zhu F.C., Zhang J., Zhang X.F., Zhou C., Wang Z.Z., Huang S.J., et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010, 376:895-902.
117. Pagliusi S. World's first hepatitis E vaccine approved in China 2012, WHO Global Immunization News, p. 14.
118. Proffitt A. First HEV vaccine approved. Nat Biotech 2012, 30:300.
119. Hepatitis B immunization. WHO position paper. Wkly Epidemiol Rec 2009, 84:405-420.
120. Hepatitis B immunization. WHO position paper. Wkly Epidemiol Rec 1998, 73:329.